DBV Technologies (NASDAQ:DBVT) Shares Pass Above 50 Day Moving Average – Time to Sell?

Shares of DBV Technologies S.A. (NASDAQ:DBVT) crossed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $3.54 and traded as high as $4.58. DBV Technologies shares last traded at $4.34, with a volume of 36,372 shares.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on DBVT shares. HC Wainwright raised their price objective on shares of DBV Technologies from $25.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, October 24th. StockNews.com initiated coverage on DBV Technologies in a research note on Saturday. They issued a “hold” rating on the stock. Finally, JMP Securities reiterated a “market outperform” rating and issued a $10.00 price objective on shares of DBV Technologies in a report on Friday, January 10th.

DBV Technologies Price Performance

The firm has a 50-day moving average of $3.56 and a 200-day moving average of $3.86.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.80) EPS for the quarter, beating analysts’ consensus estimates of ($1.90) by $1.10. The firm had revenue of $1.07 million for the quarter, compared to analysts’ expectations of $1.17 million. DBV Technologies had a negative return on equity of 106.07% and a negative net margin of 815.73%. On average, equities analysts anticipate that DBV Technologies S.A. will post -7.05 earnings per share for the current fiscal year.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.